6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-carboxylic acid

Catalog No.: 
ACPHDR679
CAS No.: 
1173003-61-6
Molecular Formula: 
C7H8N2O3
Molecular Weight: 
168.15
6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$65.00In stockInquiry
100mg95%$96.00In stockIn stock
250mg95%$137.00In stockIn stock
1g95%$415.00In stockInquiry
5g95%$1005.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-carboxylic acid
IUPAC Name6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-carboxylic acid
MDL No.MFCD16547365
Molecular FormulaC7H8N2O3
Molecular Weight168.15
SMILESO=C(C1=C2OCCCN2N=C1)O
InChI KeyLARVLEBTOMBFRH-UHFFFAOYSA-N
Synonym6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-carboxylic acid;5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-3-carboxylic acid;5H-Pyrazolo[5,1-b][1,3]oxazine-3-carboxylic acid, 6,7-dihydro-
CAS No.1173003-61-6
PubChem CID52228125

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACPHDR679 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPHDR679 route product structure diagram
    ACPHDR6791173003-61-6In Stock
Inquiry

2. ACPHDR679 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPHDR679 route product structure diagram
    ACPHDR6791173003-61-6In Stock
Inquiry

3. ACPHDR679 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPHDR679 route product structure diagram
    ACPHDR6791173003-61-6In Stock
Inquiry

Comments (0)